Literature DB >> 1900918

Characterization of the BCR promoter in Philadelphia chromosome-positive and -negative cell lines.

N P Shah1, O N Witte, C T Denny.   

Abstract

The t(9;22) Philadelphia chromosome translocation fuses 5' regulatory and coding sequences of the BCR gene to the c-ABL proto-oncogene. This results in the formation of hybrid BCR-ABL mRNAs and proteins. The shift in ABL transcriptional control to the BCR promoter may play a role in cellular transformation mediated by this rearrangement. We have functionally localized the BCR promoter to a region 1 kb 5' of BCR exon 1 coding sequences by using a chloramphenicol acetyltransferase reporter gene assay. Nucleotide sequence analysis of this region revealed many consensus binding sequences for transcription factor SP1 as well as two potential CCAAT box binding factor sites and one putative helix-loop-helix transcription factor binding site. No TATA-like or "initiator" element sequences were found. Because of low steady-state levels of BCR mRNA and the high GC content (78%) of the promoter region, definitive mapping of transcription start sites required artificial amplification of BCR promoter-directed transcripts. Overexpression from the BCR promoter in a COS cell system was effective in demonstrating multiple transcription initiation sites. In order to assess the effects of chromosomal translocation on the transcriptional control of the BCR gene, we determined S1 nuclease protection patterns of poly(A)+ RNA from tumor cell lines. No differences were observed in the locations and levels of BCR transcription initiation sites between those lines that harbored the t(9;22) translocation and those that did not. This demonstrates that BCR promoter function remains intact in spite of genomic rearrangement. The BCR promoter is structurally similar to the ABL promoters. Together, this suggests that the structural fusion of BCR-ABL and not its transcriptional deregulation is primarily responsible for the transforming effect of the t(9;22) translocation.

Entities:  

Mesh:

Year:  1991        PMID: 1900918      PMCID: PMC359860          DOI: 10.1128/mcb.11.4.1854-1860.1991

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  50 in total

1.  Expression of bcr and bcr-abl fusion transcripts in normal and leukemic cells.

Authors:  S Collins; H Coleman; M Groudine
Journal:  Mol Cell Biol       Date:  1987-08       Impact factor: 4.272

2.  Cell-type specificity of immunoglobulin gene expression is regulated by at least three DNA sequence elements.

Authors:  R Grosschedl; D Baltimore
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

3.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

Authors:  G Q Daley; R A Van Etten; D Baltimore
Journal:  Science       Date:  1990-02-16       Impact factor: 47.728

4.  Identification of DNA sequences required for transcription of the human alpha 1-globin gene in a new SV40 host-vector system.

Authors:  P Mellon; V Parker; Y Gluzman; T Maniatis
Journal:  Cell       Date:  1981-12       Impact factor: 41.582

5.  Acute leukaemia in bcr/abl transgenic mice.

Authors:  N Heisterkamp; G Jenster; J ten Hoeve; D Zovich; P K Pattengale; J Groffen
Journal:  Nature       Date:  1990-03-15       Impact factor: 49.962

6.  Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma.

Authors:  Y Tsujimoto; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

7.  Heterogeneity of chromosome 22 breakpoint in Philadelphia-positive (Ph+) acute lymphocytic leukemia.

Authors:  J Erikson; C A Griffin; A ar-Rushdi; M Valtieri; J Hoxie; J Finan; B S Emanuel; G Rovera; P C Nowell; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

8.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.

Authors:  C M Gorman; L F Moffat; B H Howard
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

9.  Use of a cDNA expression vector for isolation of mouse interleukin 2 cDNA clones: expression of T-cell growth-factor activity after transfection of monkey cells.

Authors:  T Yokota; N Arai; F Lee; D Rennick; T Mosmann; K Arai
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

10.  Adenosine deaminase: characterization and expression of a gene with a remarkable promoter.

Authors:  D Valerio; M G Duyvesteyn; B M Dekker; G Weeda; T M Berkvens; L van der Voorn; H van Ormondt; A J van der Eb
Journal:  EMBO J       Date:  1985-02       Impact factor: 11.598

View more
  9 in total

1.  FIE2: A program for the extraction of genomic DNA sequences around the start and translation initiation site of human genes.

Authors:  Allen Chong; Guanglan Zhang; Vladimir B Bajic
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

Review 2.  An analysis of vertebrate mRNA sequences: intimations of translational control.

Authors:  M Kozak
Journal:  J Cell Biol       Date:  1991-11       Impact factor: 10.539

3.  Exon-skipping in BCR/ABL is induced by ABL exon 2.

Authors:  B D Lichty; S Kamel-Reid
Journal:  Biochem J       Date:  2000-05-15       Impact factor: 3.857

Review 4.  Molecular biology of chronic myeloid leukemia.

Authors:  Y Maru
Journal:  Int J Hematol       Date:  2001-04       Impact factor: 2.490

5.  Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice.

Authors:  M L Gishizky; J Johnson-White; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

6.  BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene.

Authors:  Nitesh Sharma; Vera Magistroni; Rocco Piazza; Stefania Citterio; Caterina Mezzatesta; Praveen Khandelwal; Alessandra Pirola; Carlo Gambacorti-Passerini
Journal:  Mol Cancer       Date:  2015-07-16       Impact factor: 27.401

7.  Different BCR/Abl protein suppression patterns as a converging trait of chronic myeloid leukemia cell adaptation to energy restriction.

Authors:  Silvia Bono; Matteo Lulli; Vito Giuseppe D'Agostino; Federico Di Gesualdo; Rosa Loffredo; Maria Grazia Cipolleschi; Alessandro Provenzani; Elisabetta Rovida; Persio Dello Sbarba
Journal:  Oncotarget       Date:  2016-12-20

8.  Aberrantly reduced expression of miR-342-5p contributes to CCND1-associated chronic myeloid leukemia progression and imatinib resistance.

Authors:  Yi-Ying Wu; Hsing-Fan Lai; Tzu-Chuan Huang; Yu-Guang Chen; Ren-Hua Ye; Ping-Ying Chang; Shiue-Wei Lai; Yeu-Chin Chen; Cho-Hao Lee; Wei-Nung Liu; Ming-Shen Dai; Jia-Hong Chen; Ching-Liang Ho; Yi-Lin Chiu
Journal:  Cell Death Dis       Date:  2021-10-05       Impact factor: 8.469

9.  RUNX1 transactivates BCR-ABL1 expression in Philadelphia chromosome positive acute lymphoblastic leukemia.

Authors:  Tatsuya Masuda; Shintaro Maeda; Sae Shimada; Naoya Sakuramoto; Ken Morita; Asami Koyama; Kensho Suzuki; Yoshihide Mitsuda; Hidemasa Matsuo; Hirohito Kubota; Itaru Kato; Kuniaki Tanaka; Junko Takita; Masahiro Hirata; Tatsuki R Kataoka; Tatsutoshi Nakahata; Souichi Adachi; Hideyo Hirai; Shuichi Mizuta; Kazuhito Naka; Yoichi Imai; Shinya Kimura; Hiroshi Sugiyama; Yasuhiko Kamikubo
Journal:  Cancer Sci       Date:  2021-12-28       Impact factor: 6.716

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.